Evaluation of the Effectiveness of Additional Risk Minimization Measures for Ixazomib Citrate for Relapsed/Refractory Multiple Myeloma in Japan: A Web-Based Survey Among Pharmacists.

Yoshiko Maeda Akihito Abe Seigo Seki Nobuhiro Narii Yasuhiro Katsura Yukiko Muramatsu Motonobu Sakaguchi

Published in: Pharmaceutical medicine (2024)

How to take IXA was explained to patients by pharmacists and the aRMM material was utilized at the time of the explanation, indicating that the aRMM material contributes to the promotion of the appropriate use of IXA.

Keyphrases

multiple myeloma
end stage renal disease
randomized controlled trial
ejection fraction
newly diagnosed
chronic kidney disease
systematic review
acute myeloid leukemia
acute lymphoblastic leukemia
prognostic factors
diffuse large b cell lymphoma
cross sectional
primary care
patient reported